Biological
Aidsvax clinical trials
Also written vCP1521.
- studies test it
- 14
- open now
- 0
- in phase 3
- 3
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 8
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 13
National Institute of Allergy and Infectious Diseases (NIAID) (8) · U.S. Army Medical Research and Development Command (4) · HIV Vaccine Trials Network (1) · VaxGen (1)
Often tested with
Tested in the same studies.
AIDS Vaccines (1) · HIV Envelope Protein gp120 (1)
Studies
Open first, then newest update. How each study uses aidsvax is read from its arms, and is right about nine times in ten.
Testing it · 14
- Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South AfricaCompletedPhase 2/3National Institute of Allergy and Infectious Diseases (NIAID)NCT02968849Written as ALVAC-HIV (vCP2438)
- Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult ParticipantsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03122223Written as ALVAC-HIV (vCP2438)
- Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus ErythematosusCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03618056Written as AIDSVAX® B/E
- A Safety and Immune Response Study of 2 Experimental HIV VaccinesCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT02404311Written as ALVAC-HIV
- A Phase II Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 With or Without HIV-1 SF-2 RGP120 in HIV-1 Uninfected Adult VolunteersCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00000871Written as MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- A Randomized Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP205 Delivered by Alternate Mucosal Routes in HIV-1 Uninfected Adult VolunteersCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000884Written as MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV VaccinesCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT00076063Written as ALVAC-HIV (vCP1452)
- Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/EStatus unknownPhase 2U.S. Army Medical Research and Development CommandNCT01931358Written as ALVAC-HIV
- Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144Status unknownPhase 2U.S. Army Medical Research and Development CommandNCT01435135Written as ALVAC-HIV
- Study of Immune Responses Induced by a HIV VaccineStatus unknownPhase 2U.S. Army Medical Research and Development CommandNCT01933685Written as AIDSVAX B/E
- Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy AdultsCompletedPhase 1HIV Vaccine Trials NetworkNCT02109354Written as ALVAC-HIV
- HIV Vaccine Trial in Thai AdultsCompletedPhase 3U.S. Army Medical Research and Development CommandNCT00223080Written as ALVAC-HIV vCP1521 + AIDSVAX
- Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the ArmCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00076817Written as ALVAC-HIV (vCP205)
- Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV InfectionCompletedPhase 3VaxGenNCT00002441Written as MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
Given in every arm · 5 — aidsvax is usual care beside what is tested
- Safety and Immunogenicity of Clade C ALVAC and gp120 HIV VaccineCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT03284710Written as ALVAC-HIV (vCP2438)
- Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected AdultsTerminatedPhase 1Emergent BioSolutionsNCT02771730Written as AIDSVAX B/E
- Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected AdultsWithdrawnPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01964937Written as AIDSVAX B/E®
- Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDSCompletedPhase 1EuroVacc FoundationNCT02376582Written as AIDSVAX B/E
- Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected AdultsCompletedPhase 1HIV Vaccine Trials NetworkNCT01799954Written as AIDSVAX® B/E